Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35
Open Access
- 31 October 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0165720
Abstract
Development of fusion chimeras as potential vaccine candidates is considered as an attractive strategy to generate effective immune responses to more than one antigen using a single construct. Here, we described the design, production, purification and antigenicity of a fusion chimera (PfAMSP-Fu35), comprised of immunologically relevant regions of three vaccine target malaria antigens, PfAARP, PfMSP-3 and PfMSP-1. The recombinant PfAMSP-Fu35 is expressed as a soluble protein and purified to homogeneity with ease at a yield of ~ 7 mg L-1. Conformational integrity of the C-terminal fragment of PfMSP-1, PfMSP-119 was retained in the fusion chimera as shown by ELISA with conformation sensitive monoclonal antibodies. High titre antibodies were raised to the fusion protein and to all the three individual components in mice and rabbits upon immunization with fusion chimera in two different adjuvant formulations. The sera against PfAMSP-Fu35 recognized native parasite proteins corresponding to the three components of the fusion chimera. As shown by invasion inhibition assay and antibody mediated cellular inhibition assay, antibodies purified from the PfAMSP-Fu35 immunized serum successfully and efficiently inhibited parasite invasion in P. falciparum 3D7 in vitro both directly and in monocyte dependent manner. However, the invasion inhibitory activity of anti-AMSP-Fu35 antibody is not significantly enhanced as expected as compared to a previously described two component fusion chimera, MSP-Fu24. Therefore, it may not be of much merit to consider AMSP-Fu35 as a vaccine candidate for preclinical development.Keywords
This publication has 38 references indexed in Scilit:
- A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African InfantsNew England Journal of Medicine, 2012
- Impact of pyrethroid resistance on operational malaria control in MalawiProceedings of the National Academy of Sciences, 2012
- A Hybrid Multistage Protein Vaccine Induces Protective Immunity against Murine MalariaInfection and Immunity, 2012
- A review of malaria vaccine clinical projects based on the WHO rainbow tableMalaria Journal, 2012
- Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulationsMalaria Journal, 2011
- A Field Trial to Assess a Blood-Stage Malaria VaccineNew England Journal of Medicine, 2011
- Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern GhanaMalaria Journal, 2011
- Plasmodium falciparumMerozoite Surface Protein 1 (MSP-1)-MSP-3 Chimeric Protein: Immunogenicity Determined with Human-Compatible Adjuvants and Induction of Protective Immune ResponseInfection and Immunity, 2010
- Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51PLOS ONE, 2008
- Identification and Characterization of a Novel Plasmodium falciparum Merozoite Apical Protein Involved in Erythrocyte Binding and InvasionPLOS ONE, 2008